#United States #New York #Class Action #Securities Fraud #Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Faces Class Action Lawsuit

On February 4, 2025, Levi & Korsinsky, LLP announced that they are notifying investors in Regeneron Pharmaceuticals, Inc. about a pending class action lawsuit concerning alleged securities fraud. Regeneron, listed on NASDAQ as REGN, stands accused of engaging in practices that may have inflated their reported sales figures for one of their key products, Eylea.

Background

The class action definition seeks to recover losses for shareholders who suffered adverse impacts during the alleged fraud period from November 2, 2023, to October 30, 2024. Allegations against Regeneron suggest that the company misled investors regarding its business practices and financial health.

According to the complaint, Regeneron had been providing subsidies to distributors for credit card fees, conditioned upon not charging higher prices to customers using cards for Eylea purchases. This strategy allegedly created a misleading perception of sales growth, which does not reflect the true market performance of the product.

Allegations Detail

The complaint outlines several key points:
1. Concealed Payments: Investigators assert that Regeneron concealed payments made to distributors for credit card processing fees, which affected customer pricing and created an unfair competitive advantage in the healthcare marketplace.
2. Price Concessions: It alleges these concealed payments acted as price concessions that misrepresented Eylea’s actual market performance. The company's reported Anti-VEGF medication prices were subsequently misstated.
3. Misleading Statements: Due to these conditions, Regeneron's statements about their operational strength and product demand were materially misleading, lacking a reasonable foundation.
4. False Claims Violations: The failure to report these financial arrangements violated the False Claims Act, elevating the stakes of the lawsuit as it may carry significant legal consequences.

Next Steps for Investors

Investors who suffered losses during the specified time frame should be aware that they have until March 10, 2025, to take action by requesting the court to appoint them as lead plaintiffs. Participation in this class action does not necessitate serving in that role, and any recovery claimed may occur at no additional cost to shareholders.

Levi & Korsinsky emphasizes that class members are entitled to potential compensation without incurring any out-of-pocket costs or legal fees.

Why Choose Levi & Korsinsky?

Levi & Korsinsky boasts two decades of experience in securities litigation, during which they have secured significant settlements for aggrieved shareholders. They have often been recognized in ISS Securities Class Action Services’ Top 50 Report, showing their ongoing commitment to representing investor rights effectively. With over 70 employees at their disposal, the firm has built a reputable track record in tackling complex legal challenges that affect investors.

Contact Information

For Regeneron investors wishing to seek further information or participate in the lawsuit, please contact:

• - Joseph E. Levi, Esq.
• - Ed Korsinsky, Esq.
• - Levi & Korsinsky, LLP
• - 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: [email protected]
• - Phone: (212) 363-7500

The above details unveil the serious implications that Regeneron Pharmaceuticals may face as this class action unfolds. As the legal proceedings progress, investors must stay informed and proactive regarding their rights and potential compensations they may be entitled to within this evolving scenario.